Company Description
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions.
Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active powder-based intranasal technology, or PBI, specialized products.
To help achieve this we are focused on developing NS002, an intranasal powder Epinephrine nasal spray for the treatment of type 1 severe allergies and anaphylaxis, or Intranasal Epinephrine, and we also have been developing NS001, an intranasal Naloxone powder nasal spray for the treatment of opioid overdose, or Intranasal Naloxone.
We currently have no FDA approved products. Our products have been tested on relatively small patient populations thus far.
| Country | Israel |
| Founded | 1 |
| IPO Date | Aug 14, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dan Teleman |
Contact Details
Address: Yigal Alon 65 Tel Aviv, 6744317 Israel | |
| Phone | +972.3.573.6632 |
| Website | nasuspharma.com |
Stock Details
| Ticker Symbol | NSRX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0002029039 |
| Employer ID | 51-6022712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Udi Gilboa | Co-Founder and Executive Chairman of the Board of Directors |
| Dr. Dalia Megiddo | Co-Founder, Director, Chief Development Officer and Chief Medical Officer |
| Tair Lapidot, Pd.D. | Vice President of Research and Development and Clinical Development |
| Galia Temtsin Kryaz, Ph.D. | Director of CMC and Product Development |
| Oren Elmaliach | Director of Finance |
| Dr. Ronnie Hershman | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | EFFECT | Notice of Effectiveness |
| Aug 12, 2025 | CERT | Certification by an exchange approving securities for listing |
| Aug 8, 2025 | 8-A12B | Registration of securities |
| Aug 7, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jul 30, 2025 | FWP | Free Writing Prospectus |
| Jul 28, 2025 | FWP | Free Writing Prospectus |
| Jul 28, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jul 9, 2025 | F-1 | Registration statement for certain foreign private issuers |
| May 21, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 12, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |